Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02807181 · ClinicalTrials.gov registry record · Phase 2
SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
A Phase 2 study, sponsored by Sirtex Medical.
- Terminated
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
NCT02807181 is a Phase 2 study that was terminated before completion, run by Sirtex Medical. The registered enrollment target is 89 participants.
The verdict
NCT02807181, a Phase 2 study, was terminated before completion, sponsored by Sirtex Medical.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
Study Summary
The study planned to evaluate the benefit of applying Selective Internal Radiation Therapy (SIRT) using SIR-Spheres Y-90 resin microspheres prior to receiving systemic chemotherapy treatment (cisplatin-gemcitabine, or CIS-GEM) in patients with unresectable intrahepatic cholangiocarcinoma. Half of the patients were randomized to CIS-GEM chemotherapy plus SIRT, and half of the patients were randomized to CIS-GEM alone.
Interventions
- DRUG Cisplatin-gemcitabine
- DEVICE Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2017-02-14 |
| Est. Completion | 2021-04-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02807181
The ClinicalTrials.gov registry entry for NCT02807181 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sirtex Medical, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cisplatin-gemcitabine is the first listed.
NCT02807181 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02807181 about?
NCT02807181 is a clinical study titled "SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma". The study planned to evaluate the benefit of applying Selective Internal Radiation Therapy (SIRT) using SIR-Spheres Y-90 resin microspheres prior to receiving systemic chemotherapy treatment (cisplatin-gemcitabine, or CIS-GEM) in patients with unresectable intrahepatic cholangiocarcinoma. Half of th...
What is the current status of trial NCT02807181?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2017-02-14. Estimated completion is 2021-04-29.
What interventions are being tested in trial NCT02807181?
The interventions under investigation include: Cisplatin-gemcitabine (DRUG), Radiation: SIRT + chemotherapy (cisplatin-gemcitabine) (DEVICE).
Who is sponsoring clinical trial NCT02807181?
This trial is sponsored by Sirtex Medical, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.